The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 8, 2001, Pages 446-453

  Friedberg, Jonathan W ^a,c   Neuberg, Donna ^b   Monson, Jedidiah ^b   Jallow, Haddy ^a   Nadler, Lee M ^a,c   Freedman, Arnold S ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow transplantation; External beam radiation therapy; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; VINCRISTINE;

ABDOMEN; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AXILLA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CONDITIONING; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PELVIS; RANDOMIZATION; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0034785277     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(01)80012-4     Document Type: Article

References (58)

1. Stage I and II non-Hodgkin's lymphomas: Long-term results of radiation therapy
2. Clinical stage 1 non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy
3. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University
4. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
5. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma
6. Chemoradiotherapy for localized non-Hodgkin's lymphoma
7. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
8. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
9. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
10. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
11. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
12. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial
13. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease
14. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
15. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
16. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
17. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
18. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
19. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
20. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma
21. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study
22. Nonparametric estimation from incomplete observations
23. Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, "boost" radiation therapy, and autologous bone marrow transplantation
24. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation
25. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas
26. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survival
27. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy
28. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy
29. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)
30. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in with analysis of prognostic factors
31. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
32. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study
33. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study
34. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice
35. Cyclophosphamide 24 hours before or after total body irradiation: Effects on lung and bone marrow
36. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation
37. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients
38. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients
39. FEV1 and T-cell depletion are significant prognostic factors for severe pulmonary complications after hematopoietic stem cell transplantation
40. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
41. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
42. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
43. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
44. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
45. Myelodysplasia and acute leukemia after autologous bone marrow transplantation
46. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine and etoposide (CBV)
47. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
48. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma
49. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody
50. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
51. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy: Relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
52. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
53. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
54. Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities
55. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation: Results of a retrospective analysis on 120 patients autografted in a single institution
56. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome
57. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997
58. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies